Form 4: Tvardi Therapeutics Executive Acquires Stock Options

Jeffrey Leroy Larson, SVP of Research & Development at Tvardi Therapeutics, acquired 10,820 stock options on April 17, 2025.

Summary

• On April 17, 2025, Jeffrey Leroy Larson, the SVP of Research & Development at Tvardi Therapeutics, acquired 10,820 employee stock options.
• The exercise price of these options is $17.04.
• 25% of the shares will vest on April 17, 2026, with the remaining shares vesting monthly over the subsequent 36 months, contingent upon continuous service.
• Following the transaction, Larson directly owns 10,820 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard executive compensation transaction. The vesting schedule suggests a long-term commitment from the executive.

Future Outlook

The vesting schedule indicates a long-term incentive plan for the executive, aligning their interests with the company's performance over the next several years.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech industry where long-term research and development efforts are crucial.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially driving long-term value creation.
• Employees may view this as a positive sign of investment in key personnel.

Key Dates

Keywords

stock options, Tvardi Therapeutics, insider trading, Form 4, executive compensation, Jeffrey Leroy Larson